Sugi Predict

Sugi Predict / Targets / SSTR4

SSTR4

Somatostatin receptor type 4 · P31391 · SSTR4 on Sugi Atlas →

53,943 patent compounds predicted against SSTR4, 25,300 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL618829 SCHEMBL618829 0.56 20/20
SCHEMBL800687 SCHEMBL800687 0.51 20/20
SCHEMBL622154 SCHEMBL622154 0.50 20/20
SCHEMBL1705991 SCHEMBL1705991 0.51 19/20
SCHEMBL621689 SCHEMBL621689 0.48 19/20
SCHEMBL618828 SCHEMBL618828 0.47 19/20
SCHEMBL619418 SCHEMBL619418 0.47 19/20
SCHEMBL670479 SCHEMBL670479 0.55 18/20
SCHEMBL620781 SCHEMBL620781 0.46 17/20
SCHEMBL620949 SCHEMBL620949 0.46 17/20
SCHEMBL621314 SCHEMBL621314 0.46 17/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1163712) 0.79 16/20
SCHEMBL1608808 SCHEMBL1608808 0.52 16/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL8482) 0.83 13/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1164024) 0.78 13/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL1164198) 0.69 13/20
Seglitide Seglitide (SCHEMBL242685) 0.56 13/20
Seglitide Seglitide (SCHEMBL151244) 0.56 13/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1291174) 0.39 13/20
Somatostatin Receptor Ligand Somatostatin Receptor Ligand (SCHEMBL670990) 0.60 12/20

Clinical trials — most relevant to SSTR4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors PHASE4RECRUITING
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour PHASE3COMPLETED
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET PHASE3RECRUITING
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours PHASE2RECRUITING
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer PHASE2COMPLETED
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors PHASE1/PHASE2RECRUITING
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide PHASE1/PHASE2RECRUITING
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors PHASE1/PHASE2COMPLETED
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors PHASE1/PHASE2RECRUITING
Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors PHASE1/PHASE2COMPLETED
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer PHASE2COMPLETED
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression PHASE2COMPLETED
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) PHASE2COMPLETED
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). PHASE1/PHASE2RECRUITING
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT PHASE2COMPLETED
Pasireotide LAR in Severe Polycystic Liver Disease PHASE2COMPLETED
An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours PHASE2UNKNOWN
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake PHASE2RECRUITING
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression PHASE2UNKNOWN
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms EARLY_PHASE1COMPLETED
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors EARLY_PHASE1ACTIVE_NOT_RECRUITING
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia nanNO_LONGER_AVAILABLE
Observational Study on GEP-and Pulm-NET Treated at FPG nanRECRUITING
Molecular and Whole-body MR Imaging in Lymphomas nanCOMPLETED
Exendin PET/CT for Imaging of Paragangliomas nanUNKNOWN
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) nanNOT_YET_RECRUITING
Epidemiology of Acromegaly in Denmark 1991-2010 nanUNKNOWN
Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors nanUNKNOWN
The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging nanCOMPLETED
Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SSTR4 binder may also engage these)

ProteinNameSimilarity
P49660 — 0.999 P49660 →
P30937 — 0.999 P30937 →
SSTR5 Somatostatin receptor type 5 0.988 landscape →
Q49LX5 — 0.980 Q49LX5 →
SSTR3 Somatostatin receptor type 3 0.980 landscape →
SSTR1 Somatostatin receptor type 1 0.979 landscape →
P30936 — 0.976 P30936 →
P30935 — 0.976 P30935 →
P30938 — 0.975 P30938 →
P30873 — 0.975 P30873 →
F1MV99 — 0.973 F1MV99 →
P49681 — 0.972 P49681 →
Q56UD9 — 0.972 Q56UD9 →
NPBWR1 Neuropeptides B/W receptor type 1 0.972 landscape →
P28646 — 0.972 P28646 →
Q8MJV3 — 0.970 Q8MJV3 →
P48146 — 0.967 P48146 →
O08858 — 0.966 O08858 →
NPFFR1 Neuropeptide FF receptor 1 0.962 landscape →
Q8HYC3 — 0.959 Q8HYC3 →
GALR3 Galanin receptor type 3 0.958 landscape →
HCRTR1 Orexin/Hypocretin receptor type 1 0.955 landscape →
UTS2R Urotensin-2 receptor 0.953 landscape →
O97661 — 0.953 O97661 →
Q0GBZ5 — 0.953 Q0GBZ5 →
Q8MJV2 — 0.953 Q8MJV2 →
MLNR Motilin receptor 0.952 landscape →
Q9BDQ5 — 0.951 Q9BDQ5 →
O77808 — 0.949 O77808 →
P58307 — 0.949 P58307 →